The consensus among analysts is that GenMark Diagnostics, Inc. (GNMK) is an Overweight stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 7 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.11.
GenMark Diagnostics, Inc. (NASDAQ:GNMK) trade information
Despite being -3.62% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the GNMK stock price touched $14.99- or saw a rise of 9.41%. Year-to-date, GenMark Diagnostics, Inc. shares have moved 182.33%, while the 5-day performance has seen it change -1.81%. Over the past 30 days, the shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) have changed 43.1%. Short interest in the company has seen 5.5 Million shares shorted with days to cover at 1.86.
GenMark Diagnostics, Inc. (GNMK) estimates and forecasts
Figures show that GenMark Diagnostics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +178.28% over the past 6 months, with this year growth rate of -48.78%, compared to 2.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 52.2% and 30% for the next quarter. Revenue growth from the last financial year stood is estimated to be +42.9%.
7 analysts offering their estimates for the company have set an average revenue estimate of $31.39 Million for the current quarter. 7 have an estimated revenue figure of $24.14 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $18.37 Million and $20.92 Million respectively for this quarter and the next, and analysts expect sales will grow by 70.8% for the current quarter and 15.4% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +2.3% over the past 5 years. Earnings growth for 2020 is a modest +9.4% while over the next 5 years, the company’s earnings are expected to increase by 0%.
GenMark Diagnostics, Inc. (NASDAQ:GNMK)’s Major holders
Insiders own 4.7% of the company shares, while shares held by institutions stand at 91.8% with a share float percentage of 96.32%. Investors are also buoyed by the number of investors in a company, with GenMark Diagnostics, Inc. having a total of 165 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 9.12 Million shares worth more than $37.56 Million. As of March 30, 2020, FMR, LLC held 14.73% of shares outstanding.
The other major institutional holder is Morgan Stanley, with the holding of over 4.59 Million shares as of March 30, 2020. The firm’s total holdings are worth over $18.92 Million and represent 7.42% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Health Care and Fidelity Select Portfolios – Medical Technology & Devices Port. As of March 30, 2020, the former fund manager holds about 4.04% shares in the company for having 2500000 shares of worth $10.3 Million while later fund manager owns 2.41 Million shares of worth $9.91 Million as of March 30, 2020, which makes it owner of about 3.89% of company’s outstanding stock.